VERU

VERU INC.

Nasdaq· Pharmaceutical Preparations· Inc. WI· CIK 0000863894 Biotech & Drug Discovery

$2.28 +0.07 (+3.17%)

Oct 27 4:00 PM ET · prev $2.21

Market cap

$38.2M

Nano cap

Consensus

Buy

88% Buy or better · 8 analysts

Median target

$25.00

+996% · range $24.00–28.00

1 year

−37.5%

from $3.65 · Oct 28

30 days

−9.9%

from $2.53

52-week range

$2.09–4.23

−46% from high · low Mar 27

Avg volume 20D

225.7K

Oct 6 spike 1.52M

Short interest

1.47M

≈8.6% of shares · +4.5%

Days to cover

4.9

at average volume

Insider net

+$4.8K

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 2 reports · 90 days

Balance 0 bearish · 2 bullish oldest → newest, height = score

Avg score

·High conf. 2/2

Strongest BULLISH Veru reported fiscal Q3 2026 results with a net loss of -$0.30 per share, beating the -$0.32 consensus by…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 7 VERU INC filed a shelf registration (S-3) for up to $200 million in…
R Jun 4 Veru Inc. entered a clinical supply agreement with Novo Nordisk unde…
R Jul 2 Veru Inc. entered into an at-the-market (ATM) equity Sales Agreement…
R Aug 10 Veru reported fiscal Q3 2026 results with a net loss of -$0.30 per s…
R Aug 10 Veru reported fiscal Q3 2026 results. The net loss per share improve…
B Aug 13 1 insider buy $4.8K at $2.69
E Sep 8 FDA: Veru Advances Oral Sabizabulin Following Positive Preclini…
A Oct 6 WestPark Capital initiates

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $4.8K at an average $2.69. No open-market sales. Price is 15% below their cost.
InstitutionsBULLISH

Q2 2026: 8 added (0 new), 4 trimmed or exited.
AnalystsBULLISH

7 of 8 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.325 → −$0.303 over 90 days. 1 up, 0 down in 30 days.
Short sellersSTEADY

Short interest +4.5% to 1.47M shares. 4.9 days to cover, ≈8.6% of shares.
TrendDOWNTREND

8% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	ADD	698,439	$2.2M
Alyeska Investment Group, L.P.	NEAR_EXIT	238,556	$746.7K
BlackRock, Inc.	ADD	167,084	$523.0K
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	164,450	$514.7K
JANE STREET GROUP, LLC	DOUBLED	127,853	$400.2K
RAYMOND JAMES FINANCIAL INC	ADD	84,969	$266.0K
CITADEL ADVISORS LLC	ADD	61,977	$194.0K
PRICE T ROWE ASSOCIATES INC /MD/	ADD	24,765	$78.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 88% rate it Buy or better

Strong Buy3Buy4Hold1Sell0Strong Sell0

12-month targets · 3 analysts

$2.28 $24.00 $25.00 $28.00

Price is below the lowest target. Median implies +996%.Targets as of Oct 28, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 6, 2026	WestPark Capital INITIATE	INITIATE	Buy
Jun 4, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Buy
May 15, 2026	Oppenheimer MAINTAIN	MAINTAIN	Outperform

Washington

Corporate Lobbying

2 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4

$4.8K

bought · 1 insider

sold · 0 insiders

−15.2%

vs their $2.69 cost

Date	Insider	Type	Value
Aug 13, 2026	BARNETTE K GARY Chief Scientific Officer	BUY	$4.8K
May 4, 2026	FISCH HARRY Chief Corporate Officer	AWARD	160,000 sh
May 4, 2026	BARNETTE K GARY Chief Scientific Officer	AWARD	160,000 sh
May 4, 2026	Lu Lucy Director	AWARD	104,000 sh
May 4, 2026	Rankowitz Michael L Director	AWARD	100,000 sh
May 4, 2026	Hyun Grace Director	AWARD	97,000 sh
May 4, 2026	Katzovitz Loren Mark Director	AWARD	102,000 sh
May 4, 2026	Greco Michele Chief Admin Officer and CFO	AWARD	164,000 sh

Earnings setup

Estimates

−$0.30

EPS estimate, this quarter

+7%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.325

90d

−$0.325

60d

−$0.325

30d

−$0.285

−$0.303

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.30	-$0.34–-$0.26	+6.7%	$0.00
Next Q	-$0.26	-$0.33–-$0.19	—	$0.00
Current FY	-$0.87	-$0.87–-$0.87	+27.2%	$0.00
Next FY	-$1.00	-$1.17–-$0.70	-1.5%	$0.00

Short side

FINRA· Oct 15, 2026

1,465,647

shares short

+4.5%

vs prior settlement

4.9

days to cover

≈8.6%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Sep 8, 2026 FDA

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasi

Aug 13, 2026 Insider

BARNETTE K GARY bought 1,800 shares

Chief Scientific Officer @ $2.69 ($4.8K)

Aug 10, 2026 SEC

Veru reported fiscal Q3 2026 results. The net loss per share improved to -$0.30 from -$0.50 a year ago, beating the…

8-K — Impact 7/10

Aug 10, 2026 SEC

Veru reported fiscal Q3 2026 results with a net loss of -$0.30 per share, beating the -$0.32 consensus by 6.3%. The…

PRESS-RELEASE — Impact 7/10

Jul 2, 2026 SEC

Veru Inc. entered into an at-the-market (ATM) equity Sales Agreement with Oppenheimer and Canaccord Genuity to sell up…